4/A: Verona Pharma General Counsel Amends SEC Filing to Correct Option Exercise Price

Verona Pharma plc's General Counsel, Andrew Fisher, filed an amended Form 4 with the SEC to correct a typographical error in the reported exercise price of share options.

Summary

• Andrew Fisher, General Counsel of Verona Pharma plc (VRNA), filed an amended Form 4 (Form 4/A) with the SEC.
• The amendment was filed on June 18, 2025, to correct a typographical error in the price reported on the original Form 4 filed on May 16, 2025.
• The transaction in question occurred on May 15, 2025, and involved the exercise of share options.
• Mr. Fisher acquired 80,000 Ordinary Shares through the exercise of options at a corrected price of $2.0113 per share.
• Following this transaction, Mr. Fisher beneficially owns 439,999 Ordinary Shares directly.
• He also beneficially owns 2,320,000 Share Options (Right to Buy) directly.
• Each American Depositary Share (ADS) of Verona Pharma represents eight (8) Ordinary Shares.
• The share options vested as to 25% on March 4, 2025, with the remaining shares vesting in 36 equal monthly installments thereafter.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the filing itself is a correction of a typo (neutral), the underlying event is an insider exercising options, which is generally seen as a positive sign of confidence in the company's future.

Positives

• The filing demonstrates transparency and adherence to regulatory requirements by correcting a previously reported error.
• The underlying transaction, an insider exercising share options, can be viewed as a positive signal of management's confidence in the company's future prospects.

Future Outlook

The remaining share options will vest in 36 equal monthly installments after March 4, 2025, indicating a long-term incentive structure for the General Counsel.

Management Comments

• "This amendment is being filed to correct the Reporting Person's Form 4 filed on May 16, 2025, which contained a typographical error in the price reported."

Industry Context

This filing is a routine insider transaction amendment, common across all industries for publicly traded companies, ensuring transparency in executive stock ownership and transactions. It does not provide specific insights into broader industry trends but reflects standard corporate governance practices.

Stakeholder Impact

• Shareholders: Increased transparency regarding insider transactions and holdings, reinforcing confidence in regulatory compliance.
• Employees: No direct impact mentioned, but the vesting schedule for the General Counsel's options highlights long-term incentive alignment.

Next Steps

• The remaining share options will continue to vest in 36 equal monthly installments after March 4, 2025.

Key Dates

Keywords

Verona Pharma plc, VRNA, SEC Form 4/A, Insider Trading, Beneficial Ownership, Share Options, General Counsel, Amendment, Equity Securities, American Depositary Shares